

**CLASS: A**

**PROTOCOL(S) USED IN: Intraosseous Access & Infusion**

**PHARMACOLOGY AND ACTIONS:**

- A. Depresses automaticity of Purkinje fibers thus increasing ventricular fibrillation threshold.
- B. Decreases conduction rate and force of contraction mainly at toxic levels.
- C. Single bolus effect disappears in 10-20 minutes due to redistribution in the body.
- D. Metabolic half-life is about 2 hours; toxicity develops with repeated doses.

**INDICATIONS:**

- A. Local anesthetic for IO placement.

**CONTRAINDICATIONS:**

- A. Supraventricular dysrhythmias
- B. Atrial fibrillation or flutter
- C. 2<sup>nd</sup> or 3<sup>rd</sup> degree heart blocks
- D. Hypotension

**SIDE EFFECTS AND NOTES:**

- A. Seizures, slurred speech, AMS

**ADULT DOSING:**

- A. IO insertion  
0.5 mg/kg IO not to exceed 50 mg

**PEDIATRIC DOSING:**

- A. IO Insertion  
Same as adult